You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 14, 2025

Investigational Drug Information for AZD6738


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug AZD6738?

AZD6738 is an investigational drug.

There have been 35 clinical trials for AZD6738. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.

The most common disease conditions in clinical trials are Lung Neoplasms, Breast Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are AstraZeneca, Samsung Medical Center, and Cancer Research UK.

There are five US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for AZD6738
TitleSponsorPhase
Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC PatientsAstraZenecaPhase 2
Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC PatientsIFOM, The FIRC Institute of Molecular OncologyPhase 2
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerAstraZenecaPhase 2

See all AZD6738 clinical trials

Clinical Trial Summary for AZD6738

Top disease conditions for AZD6738
Top clinical trial sponsors for AZD6738

See all AZD6738 clinical trials

US Patents for AZD6738

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD6738 ⤷  Try for Free Chemical compounds Astrazeneca AB (Sodertalje, SE) ⤷  Try for Free
AZD6738 ⤷  Try for Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try for Free
AZD6738 ⤷  Try for Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try for Free
AZD6738 ⤷  Try for Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try for Free
AZD6738 ⤷  Try for Free Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Try for Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD6738

Drugname Country Document Number Estimated Expiration Related US Patent
AZD6738 Argentina AR081859 2030-06-11 ⤷  Try for Free
AZD6738 Australia AU2011263491 2030-06-11 ⤷  Try for Free
AZD6738 Brazil BR112012031561 2030-06-11 ⤷  Try for Free
AZD6738 Canada CA2800203 2030-06-11 ⤷  Try for Free
AZD6738 Chile CL2012003503 2030-06-11 ⤷  Try for Free
AZD6738 China CN103068391 2030-06-11 ⤷  Try for Free
AZD6738 Colombia CO6640270 2030-06-11 ⤷  Try for Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Development Update and Market Projection for AZD6738

Introduction

AZD6738, also known as ceralasertib, is a promising drug candidate developed by AstraZeneca that has been making significant strides in the field of oncology and beyond. This article will delve into the current development status, mechanism of action, clinical trials, and market projections for AZD6738.

Mechanism of Action

AZD6738 is an ATP-competitive, orally bioavailable inhibitor of the Ataxia Telangiectasia and Rad3 related (ATR) serine/threonine protein kinase. ATR plays a crucial role in the DNA damage response (DDR) pathway, making it a key target for cancer therapy. By inhibiting ATR, AZD6738 disrupts cell cycle progression, leads to S-phase accumulation, and increases markers of DNA damage and replication stress, ultimately resulting in cell death, particularly in cells with compromised DNA repair mechanisms[1].

Preclinical Data

Preclinical studies have shown that AZD6738 exhibits potent inhibition of ATR with an in vitro enzyme IC50 of 0.001µM and inhibition of ATR substrate CHK1 Ser345 phosphorylation in cells at an IC50 of 0.074µM. It also demonstrates a good margin of selectivity against other kinases, with no significant inhibition of other PI3K-like kinases such as DNA-PK, ATM, mTOR, or AKT at concentrations up to 1µM[1].

Clinical Trials

Oncology

AZD6738 is currently being evaluated in several clinical trials for its efficacy in treating various types of cancer. A phase II trial is underway to assess the safety, tolerability, and clinical activity of AZD6738 in combination with the checkpoint inhibitor durvalumab in patients with previously treated advanced gastric cancer. This combination aims to enhance cancer immunotherapy by targeting the DDR pathways[2].

Another phase II trial is investigating AZD6738 alone or in combination with olaparib or durvalumab in patients with solid tumors, including renal cell carcinoma, urothelial carcinoma, pancreatic cancer, endometrial cancer, and other advanced solid tumors. This study seeks to determine whether the combination of AZD6738 with these agents can stop the growth of tumor cells more effectively than monotherapies alone[3].

Combination Therapies

AZD6738 has shown synergistic cell killing activity when combined with DNA-damaging chemotherapy agents such as cisplatin, carboplatin, gemcitabine, and bendamustine, or with ionizing radiation. These combinations have demonstrated significant enhancement of anti-tumor activity in xenograft studies, highlighting the potential of AZD6738 as a component of combination therapies in various cancer types[1].

Market Opportunity

The market for ATR inhibitors, including AZD6738, is promising due to their potential in enhancing the effectiveness of DNA-damaging cancer therapies. ATR inhibitors are being explored for use in combination therapies across various cancer types, including ovarian cancer, bile duct carcinoma, breast carcinoma, small cell cancer, and high-grade neuroendocrine cancers, as well as some hematological malignancies[4].

Competitive Landscape

AZD6738 is part of a growing class of ATR inhibitors, which also includes ATG-018, Elimusertib (BAY 1895344), and Camonsertib (RP-3500), developed by other pharmaceutical companies. The competitive landscape suggests a robust market with multiple players, each contributing to the advancement of ATR inhibition in cancer therapy[4].

Potential Beyond Oncology

Interestingly, AZD6738 is also being explored for its potential in preventing type 1 diabetes. Research has shown that AZD6738 can prevent the onset of type 1 diabetes by inducing cell death in self-antigen activated, highly proliferative diabetogenic T cells. This repurposing of AZD6738 highlights its broader therapeutic potential beyond oncology[5].

Market Projections

Given the positive preclinical and clinical data, AZD6738 is poised to make a significant impact in the oncology market. The drug's ability to enhance the efficacy of existing cancer therapies and its potential in combination regimens position it as a valuable asset in the fight against cancer.

Future Outlook

As clinical trials continue to progress, the market is likely to see increased adoption of AZD6738 in various cancer treatment protocols. The drug's oral bioavailability and favorable safety profile further support its potential for widespread use. Additionally, the exploration of AZD6738 in other therapeutic areas, such as type 1 diabetes, could expand its market reach and value.

"ATR inhibitors have shown promise in enhancing the effectiveness of DNA-damaging cancer therapies such as chemotherapy and radiation, making them potential candidates for combination therapies in various cancer types." - Kuick Research[4]

Key Takeaways

  • Mechanism of Action: AZD6738 inhibits the ATR kinase, disrupting DNA damage response pathways and leading to cell death in cancer cells.
  • Clinical Trials: Ongoing phase II trials are evaluating AZD6738 in combination with other therapies for various solid tumors and in preventing type 1 diabetes.
  • Market Opportunity: The drug has significant potential in the oncology market, particularly in combination therapies, and may also be repurposed for other conditions like type 1 diabetes.
  • Competitive Landscape: AZD6738 is part of a growing class of ATR inhibitors, with multiple pharmaceutical companies developing similar compounds.

FAQs

What is AZD6738?

AZD6738, or ceralasertib, is an orally bioavailable inhibitor of the Ataxia Telangiectasia and Rad3 related (ATR) serine/threonine protein kinase, developed by AstraZeneca.

What is the mechanism of action of AZD6738?

AZD6738 inhibits the ATR kinase, which is a key regulator of the DNA damage response pathway, leading to cell cycle disruption and increased markers of DNA damage and replication stress.

In which clinical trials is AZD6738 currently involved?

AZD6738 is being evaluated in phase II trials for its efficacy in treating various solid tumors, including gastric cancer, renal cell carcinoma, urothelial carcinoma, and pancreatic cancer, often in combination with other therapies like durvalumab or olaparib.

What is the market potential of AZD6738?

The market potential of AZD6738 is significant, particularly in the oncology sector, due to its ability to enhance the effectiveness of DNA-damaging cancer therapies and its potential in combination regimens.

Is AZD6738 being explored for uses beyond cancer?

Yes, AZD6738 is also being investigated for its potential in preventing type 1 diabetes by targeting self-antigen activated diabetogenic T cells.

What are the competitive ATR inhibitors in the market?

Other ATR inhibitors include ATG-018, Elimusertib (BAY 1895344), and Camonsertib (RP-3500), developed by companies such as Antengene, Bayer, and Repare Therapeutics.

Sources

  1. AZD6738 - AstraZeneca Open Innovation. Retrieved from https://openinnovation.astrazeneca.com/preclinical-research/preclinical-molecules/azd6738.html
  2. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with previously treated advanced gastric cancer. Retrieved from https://jitc.bmj.com/content/10/7/e005041
  3. Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors. Retrieved from https://clinicaltrials.ucsf.edu/trial/NCT03682289
  4. Global ATR Protein Inhibitors Clinical Trials and Market Opportunity. Retrieved from https://www.kuickresearch.com/report-atr-protein-inhibitors-clinical-trials
  5. An orally available cancer drug AZD6738 prevents type 1 diabetes. Retrieved from https://pubmed.ncbi.nlm.nih.gov/38164129/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.